---
layout: default
title: Sincalide
parent: 僅模型預測 (L5)
nav_order: 1164
evidence_level: L5
indication_count: 10
---

# Sincalide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Sincalide (DB09142): From an Undetermined Original Indication to "Malignant Catarrh" — A Low-Confidence Signal

## One-Sentence Summary

> Sincalide's original indication and mechanism of action are not available in the current evidence pack, and it is not marketed locally (0 licenses on file).
> The TxGNN model's top-ranked prediction is **Malignant Catarrh** (a bovine herpesvirus disease), but this signal is supported by **0 clinical trials** and **0 publications**, and the model's own rationale flags it as likely knowledge-graph noise rather than a genuine mechanistic finding.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | No data available (evidence pack lists no approved indication; drug is not marketed locally) |
| Predicted New Indication | Malignant Catarrh (rank 1) |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism-of-action data for sincalide is not available in this evidence pack, and no original indication is on record. Without a documented drug class or established indication to anchor a mechanistic comparison, the biological plausibility of the top prediction cannot be substantiated from the data provided.

More importantly, the evidence pack's own rationale for the rank-1 candidate states that Malignant Catarrhal Fever is a herpesvirus infection of cattle with **no known biological connection** to cholecystokinin/gallbladder-pancreatic signaling pathways, and explicitly characterizes the high TxGNN score as likely **knowledge-graph noise** arising from an animal-disease node rather than a real pharmacological signal. The same pattern repeats for ranks 2, 4, 6, 7, 8, 9, and 10 — all L5, all zero evidence, several of them veterinary or genetically unrelated conditions (bovine rhinotracheitis, thrombotic disease, familial hypercholesterolemia, Prinzmetal angina, amenorrhea).

The only candidates with any literature support (rank 3: cytomegalovirus infection; rank 5: hyperthyroidism) reach only L4, based on unrelated basic-science studies on pancreatic acinar cell exocytosis and thyroid-status effects on Ca²⁺ signaling in rats — mechanistically tangential and explicitly noted as indirect/off-topic by the source rationale. No candidate in this list reaches a level where human translational relevance can be inferred.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

Sincalide has **0 licenses on file** and is currently **not marketed**. No NDA, product, or approved-indication records are available for review.

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Note: key warnings, contraindications, and DDI data are all flagged as blocking data gaps — see Conclusion below.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (Malignant Catarrh) has zero clinical trial or literature support and is explicitly assessed as a likely graph-noise artifact with no plausible mechanistic link to sincalide. All ten ranked candidates are L4–L5, and none reach a level of evidence sufficient to justify advancing to safety screening (S1). In addition, a **Blocking** data gap (DG001: TFDA warnings/contraindications unavailable) independently prevents any safety evaluation regardless of indication strength.

**To proceed, the following is needed:**
- TFDA label data (warnings, contraindications) — required to clear Blocking gap DG001 before any S1 safety review
- Confirmed mechanism of action via DrugBank — required to clear High-severity gap DG002
- Documentation of sincalide's actual original/approved indication(s), currently absent from the evidence pack
- If repurposing is still of interest, re-run evidence collection focused on ranks 3 and 5 (CMV infection, hyperthyroidism) only after confirming a plausible human mechanistic pathway — current literature for both is indirect, animal-only, and insufficient on its own
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

